

# The Clinical Significance of Measles: A Review

Robert T. Perry<sup>1</sup> and Neal A. Halsey<sup>2</sup>

<sup>1</sup>National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia; <sup>2</sup>Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

**Forty years after effective vaccines were licensed, measles continues to cause death and severe disease in children worldwide. Complications from measles can occur in almost every organ system. Pneumonia, croup, and encephalitis are common causes of death; encephalitis is the most common cause of long-term sequelae. Measles remains a common cause of blindness in developing countries. Complication rates are higher in those <5 and >20 years old, although croup and otitis media are more common in those <2 years old and encephalitis in older children and adults. Complication rates are increased by immune deficiency disorders, malnutrition, vitamin A deficiency, intense exposures to measles, and lack of previous measles vaccination. Case-fatality rates have decreased with improvements in socioeconomic status in many countries but remain high in developing countries.**

Before the introduction of measles vaccines, measles virus infected 95%–98% of children by age 18 years [1–4], and measles was considered an inevitable rite of passage. Exposure was often actively sought for children in early school years because of the greater severity of measles in adults.

## CHARACTERISTIC ILLNESS

After an incubation period of 8–12 days, measles begins with increasing fever (to 39°C–40.5°C) and cough, coryza, and conjunctivitis [5, 6]. Symptoms intensify over the 2–4 days before the onset of rash and peak on the first day of rash [7]. The rash is usually first noted on the face and neck, appearing as discrete erythematous patches 3–8 mm in diameter. The lesions increase in number for 2 or 3 days, especially on the trunk and the face, where they frequently become confluent (figure 1). Discrete lesions are usually seen on the distal extremities, and with careful observation, small num-

bers of lesions can be found on the palms of 25%–50% of those infected. The rash lasts for 3–7 days and then fades in the same manner as it appeared, sometimes ending with a fine desquamation that may go unnoticed in children who are bathed daily. An exaggerated desquamation is commonly seen in malnourished children [6, 9, 10]. Fever usually persists for 2 or 3 days after the onset of the rash, and the cough may persist for as many as 10 days.

Koplik's spots usually appear 1 day before the onset of rash and persist for 2 or 3 days. These bluish-white, slightly raised, 2- to 3-mm-diameter lesions on an erythematous base appear on the buccal mucosa, usually opposite the first molar, and occasionally on the soft palate, conjunctiva, and vaginal mucosa [11, 12]. Koplik's spots have been reported in 60%–70% of persons with measles but are probably present in most persons who develop measles [13]. An irregular blotchy enanthem may be present in other areas of the buccal mucosa. Photophobia from iridocyclitis, sore throat, headache, abdominal pain, and generalized mild lymphadenopathy are also common.

Measles is transmitted by the respiratory route and is highly infectious. Infectivity is greatest in the 3 days before the onset of rash, and 75%–90% of susceptible household contacts develop the disease [14–16]. The early prerash symptoms are similar to those of other common respiratory illnesses, and affected persons often participate in routine social activities, facilitating


N.H. has research grants from Glaxo SmithKline (a manufacturer of measles vaccine) for studies of *Haemophilus influenzae* type b and Lyme disease vaccines.

Financial support: CDC cooperative agreement for the Clinical Immunization Safety Assessment (CISA) Network.

Reprints or correspondence: Dr. Neal Halsey, Dept. of International Health, Johns Hopkins Bloomberg School of Public Health, w5515, 615 N. Wolfe St., Baltimore, MD 21205 (nhalsey@jhsph.edu).

**The Journal of Infectious Diseases** 2004;189(Suppl 1):S4–16

© 2004 by the Infectious Diseases Society of America. All rights reserved.  
0022-1899/2004/18909S1-0002\$15.00



**Figure 1.** Development and distribution of measles rash. Reprinted with permission from [8].

transmission. Numerous outbreaks of disease in highly vaccinated populations occur when children in the first few days of illness attend sporting events as participants or spectators, especially indoor events such as basketball and wrestling tournaments [17–21]. Outbreaks also occur when ill children are brought to a doctor's office or emergency room for evaluation for fever, irritability, or rash [22, 23].

### MILD, MODIFIED, AND ATYPICAL MEASLES

Milder forms of measles occur in children and adults with pre-existing partial immunity. Infants who have low levels of passively acquired maternal antibody and persons who receive blood products that contain antibody often have subclinical infections or minimal symptoms that may not be diagnosed as measles [24–26]. Vaccination protects >90% of recipients against disease, but after exposure to natural measles, some vaccinees develop boosts in antibody associated with mild symptoms and may have rash with little or no fever or nonspecific respiratory symptoms [27–32]. People with inapparent subclinical measles virus

infections are not known to transmit measles virus to household contacts [33].

Atypical measles occurred in children who received formalin-inactivated (killed) measles vaccine that was in use in the United States from 1963 to 1968 [34]. These children developed high fever, a rash that was most prominent on the extremities and often included petechiae, and a high rate of pneumonitis [34–36]. Recent studies in monkeys indicate that this illness was caused by antigen-antibody immune complexes resulting from incomplete maturation of the antibody response to the vaccine [37, 38].

### COMPLICATIONS

Measles virus infects multiple organ systems and targets epithelial, reticuloendothelial, and white blood cells, including monocytes, macrophages, and T lymphocytes [39]. Pathological studies of children dying during acute measles have found multinucleated giant cells typical of measles virus infection throughout the respiratory and gastrointestinal tracts and in most lymphoid tissues [40–51]. Measles virus infection leads to a decline in CD4 lymphocytes, starting before the onset of rash and lasting for up to 1 month, and resulting in suppression of delayed-type hypersensitivity as measured by anergy to skin test antigens, including tuberculosis antigen [52–56]. Whether measles predisposes to reactivation of latent *Mycobacterium tuberculosis* infections has been a subject of debate [57].

Complications from measles have been reported in every organ system (table 1). Many of these complications are caused by disruption of epithelial surfaces and immunosuppression [70–72]. Rates of complications from measles vary by age (table 2) and underlying conditions.

### RESPIRATORY COMPLICATIONS

**Otitis media.** Otitis media is the most common complication of measles reported in the United States and occurs in 14% of children <5 years old (table 2). Presumably, inflammation of the epithelial surface of the eustachian tube causes obstruction and secondary bacterial infection. Lower rates of otitis media are noted with increasing age, most likely a function of the increasing diameter of the eustachian tube and the decreasing risk of obstruction.

**Laryngotracheobronchitis.** Laryngotracheobronchitis or “measles croup” was noted in 9%–32% of US children hospitalized with measles [73–78]. The majority of affected children were <2 years old. In one-third to one-half of such cases, culture of samples from the trachea yields positive results for bacterial pathogens, with a purulent exudate and evidence of secondary bacterial tracheitis, pneumonia, or both. The most commonly cultured organism is *Staphylococcus aureus*, although *Strepto-*

**Table 1. Complications associated with measles by organ system.**

Organ system, reference	Complications
Respiratory [58–60]	Otitis media, mastoiditis, croup (laryngotracheobronchitis), tracheitis, pneumonia, pneumothorax, mediastinal emphysema
Neurological [61]	Febrile convulsions, encephalitis, postinfectious encephalitis, inclusion body encephalitis in immunocompromised persons, subacute sclerosing pan encephalitis, Guillain-Barré syndrome, Reye's syndrome, transverse myelitis
Gastrointestinal [10, 39, 62, 63]	Diarrhea (enteritis), mesenteric adenitis, appendicitis, hepatitis, pancreatitis, stomatitis, noma (cancrum oris)
Ophthalmic [64]	Keratitis, corneal ulceration, corneal perforation, central vein occlusion, blindness
Hematologic [65]	Thrombocytopenic purpura, disseminated intravascular coagulation
Cardiovascular [39, 66, 67]	Myocarditis, pericarditis
Dermatologic [10]	Severe desquamation, cellulitis
Other [68, 69]	Hypocalcemia, myositis, nephritis, renal failure, malnutrition, death

*coccus pneumoniae*, *Haemophilus influenzae*, *Pseudomonas aeruginosa*, *Escherichia coli*, and *Enterobacter* species have also been identified [74, 76–79]. In a series of 6 children intubated because of measles croup, viral cultures revealed that 1 child was coinfecting with adenovirus and another with herpes simplex virus (HSV) [74]. Laryngotracheobronchitis was the second most common cause of death in US children hospitalized with measles, after pneumonia [73–79].

**Pneumonia.** Measles infects the respiratory tracts of nearly all affected persons. Pneumonia is the most common severe complication of measles and accounts for most measles-associated deaths [80]. In studies of unselected hospitalized children with measles, 55% had radiographic changes of bronchopneumonia, consolidation, or other infiltrates; 77% of children with severe disease and 41% of children with mild disease had radiographic changes [81]. In recent years, pneumonia was present in 9% of children <5 years old with measles in the United States (table 2), in 0%–8% of cases during outbreaks [82–87], and in 49%–57% of adults [88, 89].

Pneumonia may be caused by measles virus alone, secondary viral infection with adenovirus or HSV, or secondary bacterial infection [39, 80, 90]. Measles is one cause of Hecht's giant cell pneumonia, which usually occurs in immunocompromised persons but can occur in otherwise normal adults and children [46, 91–94]. Studies that included culture of blood, lung punctures, or tracheal aspirations revealed bacteria as the cause of 25%–35% of measles-associated pneumonia. *S. pneumoniae*, *S. aureus*, and *H. influenzae* were the most commonly isolated organisms [39, 80]. Other bacteria (e.g., *Pseudomonas* species, *Klebsiella pneumoniae*, and *E. coli*) are less common causes of severe pneumonia associated with measles. In studies of young adult military recruits with pneumonia associated with measles, *Neisseria meningitidis* was a probable cause in some cases [85, 95].

Pneumomediastinum and mediastinal emphysema have been reported as complications of measles in several countries [58, 60, 90, 96]. Some children have the clinical pattern of bronchiolitis [39]. Because viral cultures are not always done, the

possibility of coinfection with other respiratory viruses cannot be ruled out.

**Measles pneumonia in immunocompromised patients.** Among immunocompromised persons, diffuse progressive pneumonitis caused by the measles virus is the most common cause of death [97–104]. These patients may first have typical measles with pneumonia, or they may have a nonspecific illness without rash followed by pneumonitis without a rash. In general, signs of pneumonitis develop in the 2 weeks after the first onset of symptoms [90, 96, 105]. Other patients have had re-appearance of rash and pneumonitis after long intervals following “classical” measles [97, 106].

## GASTROINTESTINAL COMPLICATIONS

Measles probably infects the intestinal tracts of most persons with measles. A gastric biopsy obtained the day before rash onset from a 44-year-old man revealed characteristic giant cells that were positive for measles by immunologic staining, and 8 of 10 children exposed to the man subsequently developed measles [51]. Several cases of appendicitis have developed before and during measles rash, and characteristic giant cells typical for measles have been found in appendix tissue [42, 43, 45, 107–109].

**Diarrhea.** In the United States, 8% of all reported measles cases during 1987–2000 were complicated by diarrhea. Rates were higher in those <5 or >30 years old (table 2). Among hospitalized persons with measles in the United States, 30%–70% had diarrhea [73–78, 88, 89]. Feachem and Koblinsky [110] found that 15%–63% of measles cases from community-based studies from developing countries in the prevaccine era were complicated by diarrhea and that 9%–77% of all diarrheal deaths were measles-associated. Stools of children with measles-associated diarrhea usually have the same bacteria as those of children with diarrhea not associated with measles [111–113]. Measles-associated diarrhea typically begins just before rash onset [63], suggesting that measles virus is responsible for most of the

**Table 2. Complications by age for reported measles cases, United States, 1987–2000.**

Complication	Overall (67,032 cases with age information)	No. (%) of persons with complication, by age group				
		<5 years (n = 28,730)	5–9 years (n = 6492)	10–19 years (n = 18,580)	20–29 years (n = 9161)	>30 years (n = 4069)
Any	19,480 (29.1)	11,883 (41.4)	1173 (18.1)	2369 (12.8)	2656 (29.0)	1399 (34.4)
Death	177 (0.3)	97 (0.3)	9 (0.1)	18 (0.1)	26 (0.3)	27 (0.7)
Diarrhea	5482 (8.2)	3294 (11.5)	408 (6.3)	627 (3.4)	767 (8.4)	386 (9.5)
Encephalitis	97 (0.1)	43 (0.2)	9 (0.1)	13 (0.1)	21 (0.2)	11 (0.3)
Hospitalization	12,876 (19.2)	7470 (26.0)	612 (9.4)	1612 (8.7)	2075 (22.7)	1107 (27.2)
Otitis media	4879 (7.3)	4009 (14.0)	305 (4.7)	338 (1.8)	157 (1.7)	70 (1.7)
Pneumonia	3959 (5.9)	2480 (8.6)	183 (2.8)	363 (2.0)	554 (6.1)	379 (9.3)

Source: Centers for Disease Control and Prevention.

diarrhea episodes but that secondary bacterial or viral infections may contribute to the severity and duration of illness.

Dehydration was found in 32% of hospitalized patients in California [114]. Morley [10, 115] first described the high rates of gastrointestinal complications that occurred after measles in developing countries: mouth sores, decreased food intake, protracted diarrhea, weight loss, and precipitation of severe protein calorie malnutrition [63]. Noma (cancrum oris), a progressive oral lesion that destroys orofacial tissue, has been noted after measles in Africa [116–118] and India [119]. In young adults, measles is associated with hepatitis, hypocalcemia, and elevation of creatinine phosphokinase levels [66, 67, 85, 89, 120–123].

## NEUROLOGICAL COMPLICATIONS

**Febrile seizures.** Febrile seizures occur in 0.1%–2.3% of children with measles in the United States and England [75, 77, 124–127] and are usually benign and not associated with residual damage. Most children with uncomplicated measles have changes visible on electroencephalography, but these changes are most likely due to fever and other metabolic changes [128–130]. **Postinfectious encephalomyelitis (PIE)** occurs in 1–3 per 1000 infected persons, usually 3–10 days after onset of rash [39, 131]. Higher rates of PIE due to measles occur in adolescents and adults than in school-aged children (table 2 [124, 132, 133]). PIE usually begins with the abrupt onset of new fever, seizures, altered mental status, and multifocal neurological signs [131, 134]. Although measles virus was found in cerebrovascular endothelial cells in a person who died during the first few days of rash [135], the virus usually is not found in the central nervous systems of persons with PIE. PIE appears to be caused by an abnormal immune response that affects myelin basic protein [61, 136]. As many as 25% of people with PIE due to measles die, and ~33% of survivors have lifelong neurological sequelae, including severe retardation, motor impairment, blindness, and sometimes hemiparesis [39, 131].

**Subacute sclerosing panencephalitis (SSPE).** SSPE is caused by persistence of measles virus in central nervous system

tissue for several years, followed by a slowly progressive infection and demyelination affecting multiple areas of the brain [39, 137]. The initial SSPE symptoms, usually decreased school performance and behavioral disorders, are often misdiagnosed as psychiatric problems. Subsequently, myoclonic seizures develop, and a characteristic burst-suppression pattern may be seen on electroencephalography. Measles antibody is present in the cerebrospinal fluid. The disease slowly progresses until affected persons are in a vegetative state. Wild-type measles viruses, but not measles vaccine viruses, have been found in brain tissue [138]. SSPE occurs on average in 1 per 8.5 million persons who develop measles in the United States [139–141], but the rate appears to be higher in some other countries [141–144]. Factors responsible for persistence of measles virus in these persons are not known, nor is it known whether measles virus persists in otherwise normal hosts. Geographic clustering of SSPE occurs in several countries, and there is an increased incidence in children residing in rural areas. In 2 studies, children with SSPE had more close exposure to birds than did control subjects [140, 141]. These data suggest that as-yet-undefined environmental factors, most likely another infectious agent, contribute to this disease.

**Measles encephalitis in immunocompromised patients.** A progressive central nervous system measles virus infection, termed “measles inclusion body encephalitis,” occurs in immunocompromised persons with disorders such as human immunodeficiency virus (HIV) infection or leukemia. Onset is usually 5 weeks to 6 months after acute measles. The illness begins with mental-status changes and seizures in the absence of fever; >80% of deaths occur within weeks [145–148].

## OCULAR COMPLICATIONS

Conjunctivitis occurs in most persons with measles, and inflammation of the cornea (keratitis) is common. In a study of 61 Turkish military personnel with measles, 57% had keratitis detected by slit lamp examination [149]. In well-nourished persons, these lesions usually heal without residual damage. How-

ever, secondary bacterial (e.g., *Pseudomonas* or *Staphylococcus*) or viral infections (e.g., HSV or adenovirus) can lead to permanent scarring and blindness [150]. Vitamin A deficiency predisposes to more severe keratitis, corneal scarring, and blindness [151]. Measles associated with vitamin A deficiency is one of the most common causes of acquired blindness in children in developing countries [68, 69]. Blindness can also result from cortical damage from measles encephalitis.

## OTHER ASSOCIATIONS

Measles has been hypothesized to cause or contribute to multiple sclerosis, but available evidence is weak and inconclusive [152]. Measles or measles vaccines have been suggested to contribute to or induce autism, but available data favor rejection of these hypotheses [153–155]. Studies from different laboratories have had conflicting evidence for persistence of measles virus nucleocapsid in affected tissue from patients with otosclerosis [156, 157], Paget's disease [158], and inflammatory bowel disease [153, 159, 160].

## FACTORS AFFECTING MEASLES MORBIDITY AND MORTALITY RATES

**Sex.** Historically, males have had higher case-fatality rates than did females [13, 161]. An analysis of vital statistics data from several countries (primarily in the Americas and Europe) for the years 1950–1989 suggests that women and girls may have slightly higher mortality rates after measles than do men and boys [162], but recent surveillance data from the United States and United Kingdom show equal rates of complications for men and women (table 3 [124, 163]). Pregnant women have an increased risk of complications, including death, following measles [164].

**Age.** Complication rates, including mortality, from measles are highest in children <5 years and adults (table 2). Most infants are protected during the first months of life via ma-

ternally derived antibodies. However, when immunity is lacking, measles can be severe [165–168]. Adults more commonly have encephalitis, hepatitis, hypocalcemia, or pancreatitis after measles. The increased severity of measles in adults most likely reflects the decline in cell-mediated immunity that begins in adulthood [169, 170]. Okada et al. [55] found that young infants and adults have more severe and a longer duration of lymphopenia after measles than do children.


**Crowding.** Several studies from West Africa [171, 172] and Europe [173, 174] show that children who develop measles after within-household exposure have higher case-fatality rates than do children who are exposed to measles outside the household. This phenomenon is most likely secondary to a higher inoculum from more intensive and prolonged exposure compared with more casual exposures outside the home. In Bangladesh, Koenig et al. [175] found that children who lived in a house of <18.6 m<sup>2</sup> had 2.6 times the risk of dying from measles as that of children who lived in houses of >37 m<sup>2</sup>. In the United States, however, no relationship between crowding and measles case-fatality rates has been found [176, 177].

**Immunosuppression.** Children with defects in macrophage function only (e.g., chronic granulomatous disease) do not have increased rates of complications from measles [178–180]. Suppression of lymphocyte function, resulting from congenital defects in T lymphocyte function, bone marrow transplantation [104], chemotherapy for cancer, or immunosuppressive doses of steroids, is associated with increased severity of measles [39]. In a review of 40 measles cases in children with malignancies, 58% of children had pneumonitis, 20% had encephalitis, and 8% had both [99]. Only 60% of the case-patients had typical measles rash [99]. The fatality rate was 55% overall [99]. In some immunosuppressed patients with measles, multiple organ systems are affected [39, 40, 181–183]. Measles has developed after bone marrow transplantation even when both donor and recipient have histories of measles vaccination [104]. Patients with B cell immune deficiency syndromes without T cell ab-

**Table 3. Complication rates by sex for reported measles cases, United States, 1987–2000.**

Complication	Overall (n = 66,800 with information available)	No. (%) of persons with complication, by sex	
		Males (n = 33,898)	Females (n = 32,902)
Any	19,443 (29.1)	9740 (28.7)	9703 (29.5)
Death	177 (0.3)	93 (0.3)	84 (0.3)
Diarrhea	5473 (8.2)	2831 (8.4)	2642 (8.0)
Encephalitis	96 (0.1)	49 (0.1)	47 (0.1)
Hospitalization	12,854 (19.2)	6381 (18.8)	6473 (19.7)
Otitis media	4872 (7.3)	2542 (7.5)	2330 (7.1)
Pneumonia	3948 (5.9)	1986 (5.9)	1962 (6.0)

Source: Centers for Disease Control and Prevention.



**Figure 2.** Measles death:case ratios, New York State, 1910–1969, by decade. Reprinted with permission from [212].

normalities do not appear to have increased rates of complications associated with measles.

Children born to HIV-infected women become susceptible to measles at an earlier age than do children born to HIV-negative women because the former transmit reduced amounts of antibodies to their infants [184–186]. HIV-infected infants not taking highly active antiretroviral therapy (HAART) have decreased responses to measles vaccination and a faster decline in vaccine-induced immunity [186]. In New York City during a 1989 measles outbreak, 6 of the 12 measles deaths were in persons likely infected with HIV [187]; in 1990 and 1991, 60% of all measles-related deaths in New Jersey occurred in HIV-infected children [188]. However, a study of hospitalized children with measles in Kinshasa, Zaire, found similar rates of pneumonia, diarrhea, and death after measles in HIV-seronegative and -seropositive young children [189]. There have been no studies of HIV-infected children undergoing HAART to determine how they handle measles virus infection, but survival rates would be expected to be higher than in untreated children, because children undergoing HAART have good immune responses to measles vaccination [190, 191].

**Malnutrition.** Malnourished children have impairments in multiple aspects of the immune system, prolonged excretion of measles virus, and higher measles case-fatality rates [9, 63, 192–194]. Measles contributes to the development of malnutrition because of protein-losing enteropathy, increased metabolic demands, and decreased food intake. Children who have measles early in life have significantly lower mean weights for age than do children of the same age who do not develop measles [183, 195].

**Vitamin A deficiency.** Children with clinical or subclinical vitamin A deficiency in many developing countries have increased case-fatality rates [196, 197]. Measles and other illnesses are associated with reductions in serum retinol concentrations and may induce overt vitamin A deficiency [197, 198]. Hos-

pitalized US measles patients frequently have deficiencies in vitamin A; these children are more likely to have pneumonia or diarrhea after measles [73, 199, 200]. In countries with high measles mortality, treatment with vitamin A once daily for 2 days (200,000 IU for children  $\geq 12$  months of age or 100,000 IU for infants  $< 12$  months) is associated with an  $\sim 50\%$  reduction in mortality [196, 201–203]. The World Health Organization recommends vitamin A therapy for all children with measles [204]. For hospitalized children  $< 2$  years old with measles in the United States, the American Academy of Pediatrics recommends a single dose of vitamin A (200,000 IU for children  $\geq 12$  months; 100,000 IU for those  $< 12$  months) [205].

## BURDEN OF MEASLES

**Developed countries.** Measles case-fatality rates have declined in association with economic development and associated decreased crowding, older age at infection, improved nutrition, and treatment for secondary pneumonia [206, 207]. One hundred years ago in Scotland, the measles case-fatality rate was 30–40 deaths per 1000 cases [208]. In the United States, mortality from measles decreased from 25 per 1000 reported cases in 1912 [209, 210] to 1 per 1000 reported cases in 1962 [211]. In New York State, measles mortality decreased by  $> 15$ -fold long before the introduction of measles vaccination (figure 2) [212]. US and UK case-fatality rates were  $\sim 1$  per 1000 reported measles cases from the 1940s through the 1980s [3, 124, 133, 211]. During the past 13 years in the United States, the case-fatality rate has averaged 3 per 1000 reported measles cases (table 2). This increase is most likely due to more complete reporting of measles as a cause of death, HIV infections, and a higher proportion of cases among preschool-aged children and adults. Annual US measles deaths have declined from 408 in 1962 to 0 from 1993–present [213].

**Developing countries.** Measles remains a leading cause of

death and disability-adjusted life-years lost [214]. Community-based studies during the 1970s and 1980s revealed measles case-fatality rates of 3%–34% [215–217], 10–20 times those in industrialized countries. In 2000, the World Health Organization estimated that 30–40 million persons developed measles, resulting in 777,000 deaths, most in sub-Saharan Africa [218]. This estimate was based on expected case fatality rates. Another approach based on verbal autopsies gives a lower estimate of the number of measles-associated deaths [219, 220].


High case-fatality rates in developing countries are due to a young age at infection, crowding, underlying immune deficiency disorders, vitamin A deficiency, and lack of access to medical care. Before the introduction of measles vaccines, one-third of children in many developing countries were infected in the first and second years of life, and most children were infected before age 5 years [195, 221, 222]. An estimated 125 million preschool-aged children are estimated to have vitamin A deficiency, placing them at high risk for death, severe infection, or blindness as a result of measles [197]. In recent years, the use of vitamin A therapy for children with measles, prompt antibiotic therapy for pneumonia, and older age at time of infections have contributed to the lower case-fatality rates ( $\leq 1\%$ ) in some developing countries (figure 3) [223–228]. In Latin America [229] and southern Africa [230], achieving high vaccination rates has reduced measles mortality in these regions to near zero.

Mortality from measles increases during times of war or famine. In Ethiopia in 2000, measles was responsible for 22% of deaths in children <5 years of age and 17% of deaths in children aged 5–14 years [231]. In Afghanistan, measles case-fatality rates have been as high as 28% [232]. In 2000, there were at least 1200 measles-related deaths in Afghanistan, and the case-fatality rate was 8%–13% [233]. Case-fatality rates for people hospitalized with measles in Sydney, Australia, increased during years of economic depression but were followed by lower rates in the 1940s (figure 4) [234].


### IMPACT OF MEASLES VACCINE

Measles vaccination is one of the most cost-effective health interventions ever developed. Without the vaccine, 5 million children would die each year from measles—assuming an estimated case-fatality rate of 2%–3%. Without measles vaccination, the costs of caring for those with measles in the United States would be ~\$2.2 billion annually, and the indirect costs would be an additional \$1.6 billion [235]. Each dollar spent on measles vaccine saves \$12–\$17 in direct and indirect costs [235–237].

Measles vaccination was associated with a 36% decline in overall death rate and a 57% reduction in the rate of death directly attributable to measles or diarrhea, respiratory illness, or malnutrition in Bangladesh [238]. Koenig et al. [175] found that unvaccinated children of low socioeconomic status were



**Figure 3.** Measles case-fatality rates (CFR) versus rates of complications for children with measles in Gweru, Zimbabwe, 1967–1989. Reprinted with permission from [223].



**Figure 4.** Percentage of mortality from measles among patients admitted to Coast Hospital, Sydney, Australia, 1920–1959. Reprinted with permission from [234].

2.5 times more likely than children of high socioeconomic status to die of measles. In vaccinated populations, children of low socioeconomic status had a risk of death only 50% higher than that of children of high socioeconomic status [175]. Holt et al. [239] found that vaccinated children in households of lower socioeconomic status had a markedly higher chance of surviving to age 39 months than did unvaccinated children in households of lower socioeconomic status. Measles vaccination had a lesser effect on overall child survival in households of higher socioeconomic status.

In Haiti, Bangladesh, and sub-Saharan Africa, measles vaccination was associated with an overall reduction in mortality of 30%–86% [240]. Aaby and colleagues [240, 241] have hypothesized that measles vaccination is associated with a reduction in mortality resulting from nonspecific beneficial effects on the immune system; however, the data are not conclusive.

## SUMMARY

Measles is an important cause of serious complications and death. Pneumonia is the most frequent severe complication, and croup, diarrhea, and malnutrition precipitated by measles contribute to mortality. Encephalitis occurs in ~1 of every 1000 children with measles. Concurrent vitamin A deficiency increases rates of complications. Children <5 years of age, adults, and persons with malnutrition or immunodeficiency disorders are at increased risk of complications. In developing countries, measles case-fatality rates are 10- to 100-fold higher than in developed countries; ~770,000 children died of measles in 2000. Older age at infection, vitamin A supplementation, and antibiotic therapy for secondary bacterial infections have reduced measles-associated deaths in the developing world. Eradication of measles would be a major public health accomplishment.

## References

1. Black FL. Measles antibodies in the population of New Haven, Connecticut. *J Immunol* **1959**;83:74–83.
2. Hedrich AW. Monthly estimates of the child population “susceptible” to measles, 1900–1931, Baltimore, Maryland. *Am J Hyg* **1933**;17:613–36.
3. Langmuir AD. Medical importance of measles. *Am J Dis Child* **1962**;103:224–6.
4. Snyder MJ, McCrumb FR, Bigbee T, Schluenderberg AE, Togo Y. Observations on the seroepidemiology of measles. *Am J Dis Child* **1962**;103:250–1.
5. Measles (rubeola). In: Krugman S, Katz SL, Gershon AA, Wilfert CM, eds. *Infectious disease of children*. 9th ed. St. Louis: Mosby Year Book, **1992**:223–45.
6. Robbins FC. Measles: clinical features. *Am J Dis Child* **1962**;103:266–73.
7. Krugman S. Further-attenuated measles vaccine: characteristics and use. *Rev Infect Dis* **1983**;5:477–81.
8. Krugman S. *Infectious diseases of children*. St. Louis: Mosby, **1958**.
9. Scheifele DW, Forbes CE. Prolonged giant cell excretion in severe African measles. *Pediatrics* **1972**;50:867–73.
10. Morley DC. Measles in the developing world. *Proc R Soc Med* **1974**;67:1112–5.
11. Koplik HT. The diagnosis of the invasion of measles from a study of the exanthema as it appears on the buccal mucosa. *Arch Pediatr* **1896**;13:918–22.
12. Suringa DW, Bank LJ, Ackerman AB. Role of measles virus in skin lesions and Koplik’s spots. *N Engl J Med* **1970**;283:1139–42.
13. Babbott FL, Gordon JE. Modern measles. *Am J Med Sci* **1954**;228:334–61.
14. Chapin CV. Measles in Providence, Rhode Island, 1858–1923. *Am J Hyg* **1925**;5:635–55.
15. Hope Simpson RE. Infectiousness of communicable diseases in the household (measles, chicken pox, and mumps). *Lancet* **1952**;2:549–54.
16. Top FH. Measles in Detroit, 1935. I. Factors influencing the secondary attack rate among susceptibles at risk. *Am J Public Health* **1938**;28:935–43.
17. Centers for Disease Control. Measles among members of a drum and bugle corps—Arkansas, California, Kansas. *MMWR Morb Mortal Wkly Rep* **1983**;32:561–2, 567.
18. Centers for Disease Control and Prevention. Interstate measles transmission from a ski resort—Colorado, 1994. *MMWR Morb Mortal Wkly Rep* **1994**;43:627–9.

19. Centers for Disease Control and Prevention. Measles outbreak among school-aged children—Juneau, Alaska, 1996. *MMWR Morb Mortal Wkly Rep* **1996**; 45:777–80.
20. Ehresmann KR, Hedberg CW, Grimm MB, Norton CA, MacDonald KL, Osterholm MT. An outbreak of measles at an international sporting event with airborne transmission in a domed stadium. *J Infect Dis* **1995**; 171:679–83.
21. Orenstein WA, Irvin J, Jennings MR, et al. Measles in a rural Ohio county. *Am J Epidemiol* **1980**; 111:777–89.
22. Bloch AB, Orenstein WA, Ewing WM, et al. Measles outbreak in a pediatric practice: airborne transmission in an office setting. *Pediatrics* **1985**; 75:676–83.
23. Remington PL, Hall WN, Davis IH, Herald A, Gunn RA. Airborne transmission of measles in a physician's office. *JAMA* **1985**; 253:1574–7.
24. Bennett J, Whittle H, Samb B, Cisse B, Simondon F, Aaby P. Seroconversions in unvaccinated infants: further evidence for subclinical measles from vaccine trials in Niakhar, Senegal. *Int J Epidemiol* **1999**; 28:147–51.
25. Krugman S, Giles JP, Jacobs AM, Friedman H. Studies with a further attenuated live measles-virus vaccine. *Pediatrics* **1963**; 31:919–28.
26. Krugman S, Giles JP, Jacobs AM, Friedman H. Studies with live attenuated measles-virus vaccine: comparative clinical, antigenic, and prophylactic effects after inoculation with and without gamma-globulin. *Am J Dis Child* **1962**; 103:353–63.
27. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. *J Infect Dis* **1990**; 162:1036–42.
28. Cherry JD, Feigin RD, Lobes LA Jr, et al. Urban measles in the vaccine era: a clinical, epidemiologic, and serologic study. *J Pediatr* **1972**; 81: 217–30.
29. Edmonson MB, Addiss DG, McPherson JT, Berg JL, Circo SR, Davis JP. Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population. *JAMA* **1990**; 263:2467–71.
30. Whittle HC, Aaby P, Samb B, Jensen H, Bennett J, Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. *Lancet* **1999**; 353:98–102.
31. Lee MS, Nokes DJ, Hsu HM, Lu CF. Protective titres of measles neutralising antibody. *J Med Virol* **2000**; 62:511–7.
32. Smith FR, Curran AS, Raciti KA, Black FL. Reported measles in persons immunologically primed by prior vaccination. *J Pediatr* **1982**; 101:391–3.
33. Lievano FA, Papania MJ, Helfand RF, et al. Lack of evidence of measles virus shedding in people with inapparent measles virus infections. *J Infect Dis* **2004**; 189(Suppl 1):S165–70.
34. Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. *JAMA* **1967**; 202:1075–80.
35. Nader PR. Atypical exanthem following exposure to natural measles: eleven cases in children previously inoculated with killed vaccine. *J Pediatr* **1968**; 72:22–8.
36. Rauh LW, Schmidt R. Measles immunization with killed virus vaccine: serum antibody titers and experience with exposure to measles epidemic. *Am J Dis Child* **1965**; 109:232–7.
37. Polack FP, Auwaerter PG, Lee SH, et al. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. *Nat Med* **1999**; 5:629–34.
38. Polack FP, Lee SH, Permar S, et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles [see comments]. *Nat Med* **2000**; 6:776–81.
39. Cherry JD. Measles. In: Feigin RD, Cherry JD, eds. *Textbook of pediatric infectious diseases*. 4th ed. Philadelphia: WB Saunders, **1998**: 2054–74.
40. Archibald RW, Weller RO, Meadow SR. Measles pneumonia and the nature of the inclusion-bearing giant cells: a light- and electron-microscope study. *J Pathol* **1971**; 103:27–34.
41. Corbett EU. The visceral lesions in measles, with a report of Koplik spots in the colon. *Am J Pathol* **1945**; 21:905–14.
42. Davidsohn I, Mora JM. Appendicitis in measles. *Arch Pathol* **1932**; 14:757–65.
43. Degen JA. Visceral pathology in measles: a clinico-pathological study of 100 fatal cases. *Am J Med Sci* **1937**; 194:104–11.
44. Denton J. The pathology of fatal measles. *Am J Med Sci* **1925**; 169: 531–43.
45. Herzberg M. Giant cells in the lymphoid tissue of the appendix in the prodromal stage of measles: report of an isolated case. *JAMA* **1932**; 98:139–40.
46. Lucke B. Postmortem findings in measles bronchopneumonia and other acute infections. *JAMA* **1918**; 70:2006–11.
47. Milles G. Measles-pneumonia (with a note on the giant cells of measles). *Am J Clin Pathol* **1945**; 15:334–8.
48. Monif GR, Hood CI. Ileocolitis associated with measles (rubeola). *Am J Dis Child* **1970**; 120:245–7.
49. Roberts GBS, Bain AD. The pathology of measles. *J Pathol Bacteriol* **1958**; 76:111–8.
50. Sheehy TW, Artenstein MS, Green RW. Small intestinal mucosa in certain viral diseases. *JAMA* **1964**; 190:1023–8.
51. Vieth M, Dirshmid K, Oehler U, Helpap B, von Luckner AG, Stolte M. Acute measles gastric infection. *Am J Surg Pathol* **2001**; 25:259–62.
52. Auwaerter PG, Rota PA, Elkins WR, et al. Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains. *J Infect Dis* **1999**; 180:950–8.
53. Joffe MI, Sukha NR, Rabson AR. Lymphocyte subsets in measles. Depressed helper/inducer subpopulation reversed by in vitro treatment with levamisole and ascorbic acid. *J Clin Invest* **1983**; 72:971–80.
54. Moss WJ, Ryon JJ, Monze M, Cutts F, Quinn TC, Griffin DE. Suppression of human immunodeficiency virus replication during acute measles. *J Infect Dis* **2002**; 185:1035–42.
55. Okada H, Kobune F, Sato TA, et al. Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients. *Arch Virol* **2000**; 145:905–20.
56. Griffin DE, Ward BJ. Differential CD4 T cell activation in measles. *J Infect Dis* **1993**; 168:275–81.
57. Flick JA. Does measles really predispose to tuberculosis? *Am Rev Respir Dis* **1976**; 114:257–65.
58. Crosse BA. Subcutaneous and mediastinal emphysema complication of measles [letter]. *J Infect* **1989**; 19:190.
59. Markowitz LE, Nieburg P. The burden of acute respiratory infection due to measles in developing countries and the potential impact of measles vaccine. *Rev Infect Dis* **1991**; 13(Suppl 6):S555–61.
60. Sharma A. A rare complication of measles: subcutaneous and mediastinal emphysema. *J Trop Med Hyg* **1993**; 96:169–71.
61. Johnson RT. Inflammatory and demyelinating diseases. In: Johnson RT, ed. *Viral infections of the nervous system*. 2nd ed. Philadelphia: Lippincott-Raven, **1998**:227–64.
62. Cohen N, Golik A, Blatt A, et al. Pancreatic enzyme elevation in measles. *J Clin Gastroenterol* **1994**; 19:292–5.
63. Koster FT, Curlin GC, Aziz KM, Haque A. Synergistic impact of measles and diarrhoea on nutrition and mortality in Bangladesh. *Bull World Health Organ* **1981**; 59:901–8.
64. Sommer A. Xerophthalmia, keratomalacia, and nutritional blindness. *Int Ophthalmol* **1990**; 14:195–9.
65. Hudson JB, Weinstein L, Chang TW. Thrombocytopenic purpura in measles. *J Pediatr* **1956**; 48:48–56.
66. Gavish D, Kleinman Y, Morag A, Chajek-Shaul T. Hepatitis and jaundice associated with measles in young adults. An analysis of 65 cases. *Arch Intern Med* **1983**; 143:674–7.
67. Leibovici L, Sharir T, Kalter-Leibovici O, Alpert G, Epstein LM. An outbreak of measles among young adults. Clinical and laboratory features in 461 patients. *J Adolesc Health Care* **1988**; 9:203–7.
68. Wairagkar NS, Gandhi BV, Katrak SM, Shaikh NJ, Parikh PR, Wadia NH, et al. Acute renal failure with neurological involvement in adults associated with measles virus isolation. *Lancet* **1999**; 354:992–5.

69. Casanova-Cardiel LJ, Hermida-Escobedo C. Sarampión en el adulto joven: características clínicas en 201 casos. *Rev Invest Clin* **1994**; 46: 93–8.
70. Atabani SF, Byrnes AA, Jaye A, et al. Natural measles causes prolonged suppression of interleukin-12 production. *J Infect Dis* **2001**; 184:1–9.
71. Griffin DE, Ward BJ, Esolen LM. Pathogenesis of measles virus infection: an hypothesis for altered immune responses. *J Infect Dis* **1994**; 170(Suppl 1):S24–31.
72. Schneider-Schaulies S, ter Meulen V. Pathogenic aspects of measles virus infections. *Arch Virol Suppl* **1999**; 15:139–58.
73. Butler JC, Havens PL, Sowell AL, et al. Measles severity and serum retinol (vitamin A) concentration among children in the United States. *Pediatrics* **1993**; 91:1176–81.
74. Fortenberry JD, Mariscalco MM, Louis PT, Stein F, Jones JK, Jefferson LS. Severe laryngotracheobronchitis complicating measles. *Am J Dis Child* **1992**; 146:1040–3.
75. Makhene MK, Diaz PS. Clinical presentations and complications of suspected measles in hospitalized children. *Pediatr Infect Dis J* **1993**; 12:836–40.
76. Manning SC, Ridenour B, Brown OE, Squires J. Measles: an epidemic of upper airway obstruction. *Otolaryngol Head Neck Surg* **1991**; 105: 415–8.
77. Mason WH, Ross LA, Lanson J, Wright HT Jr. Epidemic measles in the postvaccine era: evaluation of epidemiology, clinical presentation and complications during an urban outbreak. *Pediatr Infect Dis J* **1993**; 12: 42–8.
78. Ross LA, Mason WH, Lanson J, Deakers TW, Newth CJ. Laryngotracheobronchitis as a complication of measles during an urban epidemic. *J Pediatr* **1992**; 121:511–5.
79. Swift JD, Barruga MC, Perkin RM, van Stralen D. Respiratory failure complicating rubeola. *Chest* **1993**; 104:1786–7.
80. Hussey GD, Clements CJ. Clinical problems in measles case management. *Ann Trop Paediatr* **1996**; 16:307–17.
81. Kohn JL, Koiransky H. Successive roentgenograms of the chest of children during measles. *Am J Dis Child* **1929**; 38:258–70.
82. Centers for Disease Control and Prevention. Update: measles outbreak—Chicago, 1989. *MMWR Morb Mortal Wkly Rep* **1990**; 39:317–9, 325–6.
83. Dales LG, Kizer KW, Rutherford GW, Pertowski CA, Waterman SH, Woodford G. Measles epidemic from failure to immunize. *West J Med* **1993**; 159:455–64.
84. Davis RM, Whitman ED, Orenstein WA, Preblud SR, Markowitz LE, Hinman AR. A persistent outbreak of measles despite appropriate prevention and control measures. *Am J Epidemiol* **1987**; 126:438–9.
85. Gremillion DH, Crawford GE. Measles pneumonia in young adults. An analysis of 106 cases. *Am J Med* **1981**; 71:539–42.
86. McGrath D, Swanson R, Weems S, Mack D, Barbour SD. Analysis of a measles outbreak in Kent County, Michigan, in 1990. *Pediatr Infect Dis J* **1992**; 11:385–9.
87. Wyll SA, Witte JJ. Measles in previously vaccinated children. An epidemiological study. *JAMA* **1971**; 216:1306–10.
88. Henneman PL, Birnbaumer DM, Cairns CB. Measles pneumonitis. *Ann Emerg Med* **1995**; 26:278–82.
89. Wong RD, Goetz MB. Clinical and laboratory features of measles in hospitalized adults. *Am J Med* **1993**; 95:377–83.
90. Quiambao BP, Gatchalian SR, Halonen P, et al. Coinfection is common in measles-associated pneumonia. *Pediatr Infect Dis J* **1998**; 17: 89–93.
91. Chapnick EK, Gradon JD, Kim YD, et al. Fatal measles pneumonia in an immunocompetent patient—case report. *Clin Infect Dis* **1992**; 15:377–9.
92. Kaschula RO, Druker J, Kipps A. Late morphologic consequences of measles: a lethal and debilitating lung disease among the poor. *Rev Infect Dis* **1983**; 5:395–404.
93. Kipps A, Kaschula RO. Virus pneumonia following measles: a virological and histological study of autopsy material. *S Afr Med J* **1976**; 50: 1083–8.
94. Martin LT, Counahan R, Tait R, Cosgrove JF. Fatal measles giant cell pneumonia. *Ir Med J* **1982**; 75:252–3.
95. Loukides S, Panagou P, Kolokouris D, Kalogeropoulos N. Bacterial pneumonia as a suprainfection in young adults with measles. *Eur Respir J* **1999**; 13:356–60.
96. Yalaburgi SB. Subcutaneous and mediastinal emphysema following respiratory tract complications in measles. *S Afr Med J* **1980**; 58:521–4.
97. Carmena J, Tornero C, Salcedo M, Perpina J, Pons E. Neumonía por sarampión en embarazada portadora de anticuerpos para el HIV. Respuesta al tratamiento con inmunoglobulinas. *Enferm Infecc Microbiol Clin* **1996**; 14:456–7.
98. Forni AL, Schluger NW, Roberts RB. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. *Clin Infect Dis* **1994**; 19:454–62.
99. Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. *JAMA* **1992**; 267:1237–41.
100. Krasinski K, Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. *JAMA* **1989**; 261:2512–6.
101. Lewis MJ, Cameron AH, Shah KJ, Purdham DR, Mann JR. Giant-cell pneumonia caused by measles and methotrexate in childhood leukaemia in remission. *Br Med J* **1978**; 1:330–1.
102. Lipsey AI, Kahn MJ, Bolande RP. Pathologic variants of congenital hypogammaglobulinemia: an analysis of 3 patients dying of measles. *Pediatrics* **1967**; 39:659–74.
103. Markowitz LE, Chandler FW, Roldan EO, et al. Fatal measles pneumonia without rash in a child with AIDS. *J Infect Dis* **1988**; 158:480–3.
104. Nakano T, Shimono Y, Sugiyama K, et al. Clinical features of measles in immunocompromised children. *Acta Paediatr Jpn* **1996**; 38:212–7.
105. Gray MM, Hann IM, Glass S, Eden OB, Jones PM, Stevens RF. Mortality and morbidity caused by measles in children with malignant disease attending four major treatment centres: a retrospective review. *Br Med J (Clin Res Ed)* **1987**; 295:19–22.
106. Siegel MM, Walter TK, Ablin AR. Measles pneumonia in childhood leukemia. *Pediatrics* **1977**; 60:38–40.
107. Pancharoen C, Ruttanamongkol P, Suwangool P, Likitnukul S, Thisyakorn U. Measles-associated appendicitis: two case reports and literature review. *Scand J Infect Dis* **2001**; 33:632–3.
108. Searle A, Owen WJ. Measles appendicitis [case report]. *Br J Clin Pract* **1990**; 44:749.
109. Whalen TV, Klos JR, Kovalcik PJ, Cross GH. Measles and appendicitis. *Am Surg* **1980**; 46:412–3.
110. Feachem RG, Koblinsky MA. Interventions for the control of diarrhoeal diseases among young children: measles immunization. *Bull World Health Organ* **1983**; 61:641–52.
111. Greenberg BL, Sack RB, Salazar-Lindo E, et al. Measles-associated diarrhea in hospitalized children in Lima, Peru: pathogenic agents and impact on growth. *J Infect Dis* **1991**; 163:495–502.
112. Sang FC, Kangethe SK, Orinda VA, Gatheru Z, Black RE, Waiyaki PG. *Escherichia coli* associated with acute measles and diarrhoea at Kenyatta National Hospital, Kenya. *East Afr Med J* **1992**; 69:135–9.
113. Varavithya W, Aswasuwana S, Phuapradit P, Louisirirotchanakul S, Supavej S, Nopchinda S. Etiology of diarrhea in measles. *J Med Assoc Thai* **1989**; 72:151–4.
114. Chavez GF, Ellis AA. Pediatric hospital admissions for measles. Lessons from the 1990 epidemic. *West J Med* **1996**; 165:20–5.
115. Morley D. Severe measles in the tropics. I. *Br Med J* **1969**; 1:297–300.
116. Comney JO, Richardson JE. Measles in Ghana—1973–1982. *Ann Trop Paediatr* **1984**; 4:189–94.
117. Enwonwu CO, Falkler WA Jr, Idigbe EO, Savage KO. Noma (cancrum oris): questions and answers. *Oral Dis* **1999**; 5:144–9.
118. Hendrickse RG, Sherman PM. Morbidity and mortality from measles in children seen at University College Hospital, Ibadan. *Arch Virusforsch* **1965**; 16:27–34.
119. Krishnamurthy KA, Anantharaman V. Measles—a dangerous disease: a study of 1000 cases in Madurai. *Indian Pediatr* **1974**; 11:267–71.
120. Ackerman Z, Ackerman E, Shouval D. Measles: clinical and laboratory

- observations in young adults during an epidemic. *South Med J* **1988**; 81:1396–400.
121. Giladi M, Schulman A, Kedem R, Danon YL. Measles in adults: a prospective study of 291 consecutive cases. *Br Med J (Clin Res Ed)* **1987**; 295:1314.
  122. Morcos NC, McHugh H. Pancreatitis associated with measles in a young adult. *J Natl Med Assoc* **1997**; 89:435, 437.
  123. Mouallem M, Friedman E, Pazner R, Farfel Z. Measles epidemic in young adults. Clinical manifestations and laboratory analysis in 40 patients. *Arch Intern Med* **1987**; 147:1111–3.
  124. Miller DL. Frequency of complications of measles, 1963: report on a national inquiry by the Public Health Laboratory Service in collaboration with the Society of Medical Officers of Health. *Br Med J* **1964**; 5401:75–8.
  125. Vaccination against measles: clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Second report to the Medical Research Council by the Measles Vaccines Committee. *Br Med J* **1968**; 2:449–52.
  126. Vaccination against measles. Clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Third report to the Medical Research Council by the Measles Vaccines Committee. *Practitioner* **1971**; 206:458–66.
  127. Centers for Disease Control. Measles—Los Angeles County, California, 1988. *MMWR Morb Mortal Wkly Rep* **1989**; 38:49–52, 57.
  128. Gibbs FA, Gibbs EL, Carpenter PR, Spies HW. Electroencephalographic abnormality in “uncomplicated” childhood diseases. *JAMA* **1959**; 171: 1050–5.
  129. Hanninen P, Arstila P, Lang H, Salmi A, Panelius M. Involvement of the central nervous system in acute, uncomplicated measles virus infection. *J Clin Microbiol* **1980**; 11:610–3.
  130. Pampiglione G. Prodromal phase of measles: some neurophysiological studies. *Br Med J* **1964**; :1296–300.
  131. Miller HG, Stanton JB, Gibbons JL. Para-infectious encephalomyelitis and related syndromes: a critical review of the neurological complications of certain specific fevers. *Q J Med* **1956**; 25:427–505.
  132. Bloch AB, Orenstein WA, Wassilak SG, et al. Epidemiology of measles and its complications. In: Gruenberg E, Lewis C, Goldston SE, eds. *Vaccinating against brain syndromes: the campaign against measles and rubella*. New York: Oxford University Press, **1986**:5–20.
  133. Miller CL. Severity of notified measles. *Br Med J* **1978**; 1:1253.
  134. Boughton CR. Morbilli in Sydney. Part II. Neurological sequelae of morbilli. *Med J Aust* **1964**; 212:908–15.
  135. ter Meulen V, Muller D, Kackell Y, Katz M, Meyermann R. Isolation of infectious measles virus in measles encephalitis. *Lancet* **1972**; 2: 1172–5.
  136. Johnson RT, Griffin DE, Hirsch RL, et al. Measles encephalomyelitis—clinical and immunologic studies. *N Engl J Med* **1984**; 310:137–41.
  137. Tellez-Nagel I, Harter DH. Subacute sclerosing leukoencephalitis. I. Clinico-pathological, electron microscopic and virological observations. *J Neuropathol Exp Neurol* **1966**; 25:560–81.
  138. Ohuchi M, Ohuchi R, Mifune K, Ishihara T, Ogawa T. Characterization of the measles virus isolated from the brain of a patient with immunosuppressive measles encephalitis. *J Infect Dis* **1987**; 156:436–41.
  139. Centers for Disease Control. Subacute sclerosing panencephalitis surveillance—United States. *MMWR Morb Mortal Wkly Rep* **1982**; 31: 585–8.
  140. Detels R, Brody JA, McNew J, Edgar AH. Further epidemiological studies of subacute sclerosing panencephalitis. *Lancet* **1973**; 2:11–4.
  141. Halsey NA, Modlin JF, Jabbour JT, Dubey L, Eddins DL, Ludwig DD. Risk factors in subacute sclerosing panencephalitis: a case-control study. *Am J Epidemiol* **1980**; 111:415–24.
  142. Halsey NA, Modlin JF, Jabbour JT. Subacute sclerosing panencephalitis (SSPE): an epidemiologic review. In: Stevens JG, Todaro GJ, Fox CF, eds. *Persistent viruses*. New York: Academic Press, **1978**:101–14.
  143. Modlin JF, Jabbour JT, Witte JJ, Halsey NA. Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis. *Pediatrics* **1977**; 59:505–12.
  144. Yalaz K, Anlar B, Renda Y, Aysun S, Topcu M, Ozdirim E. Subacute sclerosing panencephalitis in Turkey: epidemiological features. *J Trop Pediatr* **1988**; 34:301–5.
  145. Aicardi J, Goutieres F, Arsenio-Nunes ML, Lebon P. Acute measles encephalitis in children with immunosuppression. *Pediatrics* **1977**; 59:232–9.
  146. Colamaria V, Marradi P, Merlin D, et al. Acute measles encephalitis of the delayed type in an immunosuppressed child. *Brain Dev* **1989**; 11: 322–6.
  147. Hughes I, Jenney ME, Newton RW, Morris DJ, Klapper PE. Measles encephalitis during immunosuppressive treatment for acute lymphoblastic leukaemia. *Arch Dis Child* **1993**; 68:775–8.
  148. Mustafa MM, Weitman SD, Winick NJ, Bellini WJ, Timmons CF, Siegel JD. Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. *Clin Infect Dis* **1993**; 16:654–60.
  149. Kayikcioglu O, Kir E, Soyler M, Guler C, Irkec M. Ocular findings in a measles epidemic among young adults. *Ocul Immunol Inflamm* **2000**; 8:59–62.
  150. Foster A, Sommer A. Childhood blindness from corneal ulceration in Africa: causes, prevention, and treatment. *Bull World Health Organ* **1986**; 64:619–23.
  151. Foster A, Sommer A. Corneal ulceration, measles, and childhood blindness in Tanzania. *Br J Ophthalmol* **1987**; 71:331–43.
  152. Ohara Y. Multiple sclerosis and measles virus. *Jpn J Infect Dis* **1999**; 52: 198–200.
  153. Halsey NA, Hyman SL. Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12–13, 2000 [review]. *Pediatrics* **2001**; 107:E84.
  154. Stratton K, Gable A, Shetty P, McCormick M. Immunization safety review: measles-mumps-rubella vaccine and autism. Washington, DC: National Academy Press, **2001**.
  155. Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. *BMJ* **2002**; 324:393–6.
  156. Chole RA, McKenna M. Pathophysiology of otosclerosis. *Otol Neurotol* **2001**; 22:249–57.
  157. Niedermeyer HP, Arnold W, Neubert WJ, Sedlmeier R. Persistent measles virus infection as a possible cause of otosclerosis: state of the art. *Ear Nose Throat J* **2000**; 79:552–4, 556, 558 passim.
  158. Reddy SV, Menaa C, Singer FR, et al. Measles virus nucleocapsid transcript expression is not restricted to the osteoclast lineage in patients with Paget’s disease of bone. *Exp Hematol* **1999**; 27:1528–32.
  159. Afzal MA, Armitage E, Ghosh S, Williams LC, Minor PD. Further evidence of the absence of measles virus genome sequence in full thickness intestinal specimens from patients with Crohn’s disease. *J Med Virol* **2000**; 62:377–82.
  160. Wakefield AJ, Montgomery SM. Measles virus as a risk for inflammatory bowel disease: an unusually tolerant approach. *Am J Gastroenterol* **2000**; 95:1389–92.
  161. Aaby P, Oesterle H, Dietz K, Becker N. Case-fatality rates in severe measles outbreak in rural Germany in 1861. *Lancet* **1992**; 340:1172.
  162. Garenne M. Sex differences in measles mortality: a world review. *Int J Epidemiol* **1994**; 23:632–42.
  163. Barkin RM. Measles mortality: a retrospective look at the vaccine era. *Am J Epidemiol* **1975**; 102:341–9.
  164. Atmar RL, Englund JA, Hammill H. Complications of measles during pregnancy. *Clin Infect Dis* **1992**; 14:217–26.
  165. Celers J. Problèmes de Santé Publique posés par la rougeole dans les pays favorisés. *Arch Virusforsch* **1965**; 16:5–18.
  166. Christensen PE, Schmidt H, Bang HO, Andersen V, Jordal B, Jensen O. An epidemic of measles in southern Greenland, 1951. Measles in virgin soil. II. The epidemic proper. *Acta Med Scand* **1953**; 144:450–49.
  167. Cliff AD, Haggett P, Smallman-Raynor M. Measles: an historical ge-

- ography of a major human viral disease from global expansion to local retreat, 1840–1990. Oxford, UK: Blackwell, **1993**.
168. Peart AFW, Nagler FP. Measles in the Canadian arctic, 1952. *Can J Public Health* **1954**; 45:146–57.
  169. Castle SC. Clinical relevance of age-related immune dysfunction. *Clin Infect Dis* **2000**; 31:578–85.
  170. Khanna KV, Markham RB. A perspective on cellular immunity in the elderly. *Clin Infect Dis* **1999**; 28:710–3.
  171. Aaby P, Coovadia H. Severe measles: a reappraisal of the role of nutrition, overcrowding, and virus dose. *Med Hypotheses* **1985**; 18:93–112.
  172. Aaby P. Malnutrition and overcrowding/intensive exposure in severe measles infection: review of community studies. *Rev Infect Dis* **1988**; 10:478–91.
  173. Aaby P, Bukh J, Lisse IM, Smits AJ. Severe measles in Sunderland, 1885: a European-African comparison of causes of severe infection. *Int J Epidemiol* **1986**; 15:101–7.
  174. Burstrom B, Diderichsen F, Smedman L. Child mortality in Stockholm during 1885–1910: the impact of household size and number of children in the family on the risk of death from measles. *Am J Epidemiol* **1999**; 149:1134–41.
  175. Koenig MA, Bishai D, Khan MA. Health interventions and health equity: the example of measles vaccination in Bangladesh. *Popul Dev Rev* **2001**; 27:283–302.
  176. Butler JC, Proctor ME, Fessler K, Hopfensperger DJ, Sosin DM, Davis JP. Household-acquisition of measles and illness severity in an urban community in the United States. *Epidemiol Infect* **1994**; 112:569–77.
  177. Sutter RW, Markowitz LE, Bennetch JM, Morris W, Zell ER, Preblud SR. Measles among the Amish: a comparative study of measles severity in primary and secondary cases in households. *J Infect Dis* **1991**; 163:12–6.
  178. American Academy of Pediatrics. Immunization in special clinical circumstances: immunocompromised children. In: Pickering LK, ed. 2000 red book: report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics, **2000**:56–67.
  179. Buescher ES. Infectious complications of dysfunction/deficiency of polymorphonuclear and mononuclear phagocytes. In: Long SS, Pickering LK, Prober CG, eds. Principles and practices of pediatric infectious diseases. New York: Churchill Livingstone, **1997**:715–24.
  180. Patrick CC, Slobod KS. Opportunistic infections in the compromised host. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases. 4th ed. Philadelphia: WB Saunders, **1998**:980–94.
  181. Breitbart V, Hashida Y, Sherman FE, Odagiri K, Yunis EJ. Fatal measles infection in children with leukemia. *Lab Invest* **1973**; 28:279–91.
  182. Mitus A, Enders JF, Craig JM, Holloway A. Persistence of measles virus and depression of antibody formation in patients with giant-cell pneumonia after measles. *N Engl J Med* **1959**; 261:882–9.
  183. Vargas PA, Bernardi FD, Alves VA, et al. Uncommon histopathological findings in fatal measles infection: pancreatitis, sialoadenitis, and thyroiditis. *Histopathology* **2000**; 37:141–6.
  184. de Moraes-Pinto MI, Farhat CK, Carbonare SB, et al. Maternally acquired immunity in newborns from women infected by the human immunodeficiency virus. *Acta Paediatr* **1993**; 82:1034–8.
  185. Embree JE, Datta P, Stackiw W, et al. Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers. *J Infect Dis* **1992**; 165:262–7.
  186. Moss WJ, Cutts F, Griffin DE. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. *Clin Infect Dis* **1999**; 29:106–12.
  187. Friedman S. Measles in New York City [letter]. *JAMA* **1991**; 266:1220.
  188. Palumbo P, Hoyt L, Demasio K, Oleske J, Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. *Pediatr Infect Dis J* **1992**; 11:1008–14.
  189. Sension MG, Quinn TC, Markowitz LE, et al. Measles in hospitalized African children with human immunodeficiency virus. *Am J Dis Child* **1988**; 142:1271–2.
  190. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. *Clin Infect Dis* **2001**; 32:1090–4.
  191. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. *Pediatrics* **2003**; 111:e641–4.
  192. Chen LC, Rahman M, Sarder AM. Epidemiology and causes of death among children in a rural area of Bangladesh. *Int J Epidemiol* **1980**; 9:25–33.
  193. Smedman L, Lindeberg A, Jeppsson O, Zetterstrom R. Nutritional status and measles: a community study in Guinea-Bissau. *Ann Trop Paediatr* **1983**; 3:169–76.
  194. Dossetor J, Whittle HC, Greenwood BM. Persistent measles infection in malnourished children. *Br Med J* **1977**; 1:1633–5.
  195. Halsey NA, Boulos R, Mode F, et al. Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses. *N Engl J Med* **1985**; 313:544–9.
  196. Hussey GD, Klein M. A randomized, controlled trial of vitamin A in children with severe measles. *N Engl J Med* **1990**; 323:160–4.
  197. Sommer A, West KP. Vitamin A deficiency: health, survival, and vision. New York: Oxford University Press, **1996**.
  198. Hatun S, Tezic T, Kunak B, Cengiz AB. Vitamin A levels of children with measles in Ankara, Turkey. *Turk J Pediatr* **1995**; 37:193–200.
  199. Arrieta AC, Zaleska M, Stutman HR, Marks MI. Vitamin A levels in children with measles in Long Beach, California. *J Pediatr* **1992**; 121:75–8.
  200. Frieden TR, Sowell AL, Henning KJ, Huff DL, Gunn RA. Vitamin A levels and severity of measles. New York City. *Am J Dis Child* **1992**; 146:182–6.
  201. Barclay AJ, Foster A, Sommer A. Vitamin A supplements and mortality related to measles: a randomised clinical trial. *Br Med J (Clin Res Ed)* **1987**; 294:294–6.
  202. D'Souza RM, D'Souza R. Vitamin A for the treatment of children with measles—a systematic review. *J Trop Pediatr* **2002**; 48:323–7.
  203. D'Souza RM, D'Souza R. Vitamin A for preventing secondary infections in children with measles—a systematic review. *J Trop Pediatr* **2002**; 48:72–7.
  204. Expanded Programme on Immunization. Joint WHO/UNICEF statement on vitamin A for measles. *Wkly Epidemiol Rec* **1987**; 62:133–4.
  205. American Academy of Pediatrics. Measles. In: Pickering LK, ed. 2000 red book: report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics, **2000**:385–96.
  206. Ellison JB. Pneumonia in measles. *Arch Dis Child* **1931**; 6:37–51.
  207. Swyer R. The use of sulphonamides in measles. *Br J Child Dis* **1943**; 40:63–7.
  208. Cliff AD, Haggett P, Smallman-Raynor M. Measles: an historical geography of a major human viral disease from global expansion to local retreat, 1840–1990. Oxford, UK: Blackwell, **1993**.
  209. United States Public Health Service. Prevalence of communicable diseases. *Public Health Rep* **1914**; 29:111–27.
  210. United States Public Health Service. Vital statistics rates in the United States, 1900–1940. Washington, DC: US Public Health Service, **1947**. Available at: [http://www.cdc.gov/nchs/data/vs/vsrates1900\\_40.pdf](http://www.cdc.gov/nchs/data/vs/vsrates1900_40.pdf). Accessed 5 March **2004**.
  211. Communicable Disease Center. Reported incidence of notifiable diseases in the United States, 1962. *MMWR Morb Mortal Wkly Rep* **1962**; 11:4–5.
  212. Hinman AR. Resurgence of measles in New York. *Am J Public Health* **1972**; 62:498–503.
  213. Gindler J, Tinker S, Markowitz L, Atkinson W, Dales L, Papania MJ. Acute measles mortality in the United States, 1987–2002. *J Infect Dis* **2004**; 189(Suppl 1):S69–77.
  214. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. *Lancet* **1997**; 349:1436–42.
  215. Aaby P, Clements CJ. Measles immunization research: a review. *Bull World Health Organ* **1989**; 67:443–8.

216. Aaby P. Determinants of measles mortality: host or transmission factors? In: de la Maza LM, Peterson EM, eds. *Medical virology 10: proceedings of the 10th International Symposium on Medical Virology*. 10th ed. New York: Plenum Press, **1991**:83–116.
217. Omer MI. Measles: a disease that has to be eradicated. *Ann Trop Paediatr* **1999**; *19*:125–34.
218. WHO-UNICEF joint statement on strategies to reduce measles mortality worldwide. Geneva: World Health Organization, **2001**:1–4.
219. Jones G, Steketee RW, Black RE, Bhutta ZA, Morris SS; Bellagio Child Survival Study Group. How many child deaths can we prevent this year? *Lancet* **2003**; *362*:65–71.
220. Morris SS, Black RE, Tomaskovic L. Predicting the distribution of under-five deaths by cause in countries without adequate vital registration systems. *Int J Epidemiol* **2003**; *32*:1041–51.
221. Black FL. Measles antibody prevalence in diverse populations. *Am J Dis Child* **1962**; *103*:242–9.
222. Foege WH, Foster SO. Multiple antigen vaccine strategies in developing countries. *Am J Trop Med Hyg* **1974**; *23*:685–9.
223. Marufu T, Siziya S, Murugasampillay S, Mason E, Manyame B, Tshimanga M. Measles complications: the importance of their management in reducing mortality attributed to measles. *Cent Afr J Med* **1997**; *43*:162–5.
224. Bhaskaram P, Balakrishna N, Goud BN, Sukanya M. Post-vaccination scenario of measles: a retrospective analysis. *Natl Med J India* **1999**; *12*:111–2.
225. Bilkis MD, Barrero PR, Mistchenko AS. Measles resurgence in Argentina: 1997–8 outbreak. *Epidemiol Infect* **2000**; *124*:289–93.
226. Garenne M, Kahn K, Tollman S, Gear J. Causes of death in a rural area of South Africa: an international perspective. *J Trop Pediatr* **2000**; *46*:183–90.
227. Marufu T, Siziya S. Secular changes in rates of respiratory complications and diarrhoea among measles cases. *J Trop Pediatr* **1998**; *44*:347–50.
228. Taylor WR. Measles in Vietnamese refugee children in Hong Kong. *Epidemiol Infect* **1999**; *122*:441–6.
229. Hersh BS, Tambini G, Nogueira AC, Carrasco P, de Quadros CA. Review of regional measles surveillance data in the Americas, 1996–99. *Lancet* **2000**; *355*:1943–8.
230. Biellik R, Madema S, Taole A, et al. First 5 years of measles elimination in southern Africa: 1996–2000. *Lancet* **2002**; *359*:1564–8.
231. Salama P, Assefa F, Talley L, Spiegel P, van Der Veen A, Gotway CA. Malnutrition, measles, mortality, and the humanitarian response during a famine in Ethiopia. *JAMA* **2001**; *286*:563–71.
232. Wakeham PF. Severe measles in Afghanistan. *J Trop Pediatr Environ Child Health* **1978**; *24*:87–8.
233. Ahmad K. Measles epidemic sweeps through Afghanistan. *Lancet* **2000**; *355*:1439.
234. Boughton CR. Morbilli in Sydney: a review of 3601 cases with consideration of morbidity, mortality, and measles encephalitis. *Med J Aust* **1964**; *58*:859–65.
235. Hatziaandreu EJ, Brown RE, Halpern MT. A cost-benefit analysis of the measles-mumps-rubella (MMR) vaccine. Arlington, VA: Battelle Medical Technology Assessment and Policy Research Program, **1994**:1–65.
236. Koplan JP, White CC. An update on the benefits and costs of measles and rubella immunization. In: Gruenberg E, Lewis C, Goldston SE, eds. *Vaccinating against brain syndromes: the campaign against measles and rubella*. New York: Oxford University Press, **1986**:117–27.
237. White CC, Koplan JP, Orenstein WA. Benefits, risks and costs of immunization for measles, mumps, and rubella. *Am J Public Health* **1985**; *75*:739–44.
238. Clemens JD, Stanton BF, Chakraborty J, et al. Measles vaccination and childhood mortality in rural Bangladesh. *Am J Epidemiol* **1988**; *128*:1330–9.
239. Holt EA, Boulos R, Halsey NA, Boulos LM, Boulos C. Childhood survival in Haiti: protective effect of measles vaccination. *Pediatrics* **1990**; *85*:188–94.
240. Aaby P, Samb B, Simondon F, Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. *BMJ* **1995**; *311*:481–5.
241. Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. *BMJ* **2000**; *321*:1435–8.